全文获取类型
收费全文 | 193篇 |
免费 | 12篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 9篇 |
基础医学 | 20篇 |
口腔科学 | 1篇 |
临床医学 | 13篇 |
内科学 | 32篇 |
皮肤病学 | 4篇 |
神经病学 | 19篇 |
特种医学 | 4篇 |
外科学 | 17篇 |
综合类 | 1篇 |
预防医学 | 14篇 |
眼科学 | 7篇 |
药学 | 19篇 |
肿瘤学 | 31篇 |
出版年
2023年 | 4篇 |
2022年 | 7篇 |
2021年 | 14篇 |
2020年 | 11篇 |
2019年 | 9篇 |
2018年 | 11篇 |
2017年 | 6篇 |
2016年 | 10篇 |
2015年 | 7篇 |
2014年 | 12篇 |
2013年 | 15篇 |
2012年 | 25篇 |
2011年 | 21篇 |
2010年 | 1篇 |
2009年 | 6篇 |
2008年 | 11篇 |
2007年 | 10篇 |
2006年 | 6篇 |
2005年 | 7篇 |
2004年 | 5篇 |
2003年 | 2篇 |
2002年 | 5篇 |
排序方式: 共有205条查询结果,搜索用时 15 毫秒
1.
2.
Nishit J. Shah Mukul Navnit Chandrashekhar E. Deopujari Shraddha S. Mukerji 《Indian journal of otolaryngology and head and neck surgery》2004,56(1):71-78
Endonasal endoscopic surgery is now the preferred technique to tackle pituitary tumours. Our paper describes the stepwise
endoscopic approach for surgeons embarking on pituitary surgery. It also highlights the common pitfalls encountered during
surgery and the ways to avoid them. One must proceed in a gradual step- wise manner starting from simple exposure of the sphenoid
sinus to complete endoscopic tumour removal so us to gain the neurosurgeon’s confidence as well as develop our own skills,
confidence and ability to tackle complications. We use the endonasal paraseptal trans- sphenoidal approach. Surgery begins
with gentle packing between the middle turbinate and septum to expose the anterior sphenoid wall and expose the sphenoid astium.
The ostitum is then widened inferiorly and onto the opposite side to expose both sphenoid sinuses. The inter- sphenoid sinus
and necessary mucosa is removed to expose the sella. We then use a bone flap technique or punches to open the sella. After
incising the dura, tumour is removed with a suction curette. An endoscope holder facilitates the operation. The bone flap
is replaced at the end of surgery to reconstruct the sella. This is especially important if a CSF leak is present. Nasal packing
is usually not required. 相似文献
3.
Comorbidities in head and neck cancer: agreement between self-report and chart review. 总被引:1,自引:1,他引:0
Shraddha S Mukerji Sonia A Duffy Karen E Fowler Mumtaz Khan David L Ronis Jeffrey E Terrell 《Otolaryngology--head and neck surgery》2007,136(4):536-542
OBJECTIVES: To determine the accuracy of self-reported comorbidities compared with medical record review and the clinical and sociodemographic characteristics associated with accuracy of self-reported comorbidities. STUDY DESIGN: We conducted a prospective study of 458 newly diagnosed head and neck cancer patients using self-administered questionnaire and medical chart review data. Overall and itemwise consistency between self-report and chart review was evaluated. Social, clinical, and demographic characteristics of consistent versus inconsistent responders were analyzed. RESULTS: Seventy-four percent of patients had at least one comorbidity. There was good overall consistency between self-report and chart review (kappa = 0.50). Compared with consistent responders, inconsistent responders were found to be older (P < 0.05), have lower sleep (P < 0.05) and physical activity scores (P < 0.05), be more depressed (P < 0.05), and have more severe comorbidities (P < 0.05). CONCLUSIONS AND SIGNIFICANCE: Self-report may be considered as an alternative to chart review for comorbidity assessment in head and neck cancer patients. Younger patients, those with good general health, fewer depressive symptoms, and mild comorbidities, are more likely to give responses consistent with chart review. 相似文献
4.
5.
S. K. Vishwakarma Shraddha Jain Manisha Gupta 《Indian journal of otolaryngology and head and neck surgery》2006,58(1):87-88
Oral manifestation of tuberculosis is uncommon Tongue is the most common oral site of involvement, where the presentations
are varied. Here we report a case of primary lingual tuberculosis with an unusual presentation as a cold abscess. 相似文献
6.
Shraddha Rani Modapathi Anusha Rohit Vankadari Aditya Varsha Prakash Shetty Akshatha Kotian Praveen Rai Indrani Karunasagar Vijaya Kumar Deekshit 《Indian journal of medical microbiology》2022,40(1):74-80
PurposeBurkholderia is a Gram-negative opportunistic bacterium capable of causing severe nosocomial infections. The aim of this study was to characterize Burkholderia cepacia complex and to compare different molecular methods used in its characterization.MethodsIn this study, 45 isolates of Burkholderia cepacia complex (Bcc) isolated from clinical cases were subjected to RAPD (Random amplified polymorphic DNA), recA-RFLP (Restriction fragment length polymorphism), 16SrDNA-RFLP, whole-cell protein analysis, recA DNA sequencing and biofilm assay.ResultsOf the 45 isolates tested, 97.7% were sensitive to ceftazidime, 82.2% were sensitive to Cotrimoxazole, 73.3% were sensitive to meropenem, 55.5% were sensitive to minocycline and 42.2% were sensitive to levofloxacin. Majority of the isolates harbored all the tested virulence genes except bpeA and cblA. The RAPD generated 11 groups (R1-R11), recA-RFLP 10 groups (A1-A10), 16SrRNA-RFLP 5 groups (S1–S5) and SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide gel electrophoresis) whole cell protein analysis revealed 12 groups (C1–C12). recA sequencing revealed that most of the isolates belonging to the genomovar III Burkholderia cenocepacia. Though all the methods are found to be efficient in differentiating Burkholderia spp., recA-RFLP was highly discriminatory at 96% similarity value. The study also identified a new strain Burkholderia pseudomultivorans for the first time in the country. Further, recA sequencing could identify the strains to species level. Majority of the multidrug-resistant strains also showed moderate to strong biofilm-forming ability, which further contributes to the virulence characteristics of the pathogens.ConclusionsThe study highlights the importance of combination of molecular methods to characterize Burkholderia cepacia complex. Molecular typing of these human pathogens yields important information for the clinicians in order to initiate the most appropriate therapy in the case of severe infections and to implement preventive measures for the effective control of transmission of Burkholderia spp. 相似文献
7.
Shraddha Madanagobalane Sankarasubramanian Anandan 《Indian journal of dermatology》2013,58(4):316-Aug;58(4):316
8.
Shraddha K. Dahale S. K. Prashanthi P. U. Krishnaraj 《Proceedings of the National Academy of Sciences, India. Section B.》2016,86(3):723-734
The aim of the present study was to understand the mineral phosphate solubilization (MPS) in Rhizobium sp. MR-54 (MPS+) by using forward genetic approach and its effect on nodulation as well as nitrogen accumulation on green gram. Tn5 mutants (MPS?) were generated from the MPS+ strain by Tn5 mutagenesis. Screening 1,603 colonies of MR-54::Tn5 resulted in identification of those mutants which failed to show any solubilization zone up to 72 h after incubation on Tri-calcium phosphate medium (TCP). pH drops and Pi release were highly correlated up to 15 days after incubation in TCP broth. Gluconic acid was detected in the culture supernatants of MPS+ isolates through thin layer chromatography indicating the presence of direct oxidation pathway in MR-54 strain. Detailed characterization of mutants was carried out for related properties like colony morphology, Pi release and pH change in TCP broth, organic acid production, surface characteristics and plant growth promoting ability etc. Mutants deficient in MPS showed reduced nodulation and nitrogen accumulation in green gram under green house conditions in leonard jar apparatus over the wild strain indicating the MPS by Rhizobium being involved in nodulation, nitrogen accumulation and plant growth. 相似文献
9.
Shraddha I Cantara Crystal Gergye Vanessa K Lee Michael Huerkamp 《Journal of the American Association for Laboratory Animal Science》2022,61(2):208
Sustained-release formulations of controlled substances are commonly used to provide analgesia in research animals. These formulations represent refinements that offer the advantage of prolonged, multiday pain relief with a single injection, thereby decreasing handling stress in animals and saving time for scientists. Compounding pharmacies produce sustained-release buprenorphine for veterinary use (i.e., buprenorphine SR-LAB); one of these pharmacies has shortened the original 6-mo shelf-life to 28 d to comply with United States Pharmacopeia standards for ensuring sterility. This limitation risks increasing the waste of controlled substances, which require an expensive destruction process that is legally enforced in our state. To assess whether the sterility of buprenorphine SR-LAB is preserved for at least 6 mo in a general laboratory setting, we tested 5 bottles for the presence of endotoxin and bacterial and fungal contamination monthly for 6 mo. Overall, results of the study showed that the bottles remained sterile over the 6-mo duration as no endotoxin was detected and the bottles did not become contaminated with bacteria or fungi. In conclusion, when stored securely and used with aseptic handling techniques, buprenorphine SR-LAB can be maintained in a sterile state for 6 mo in a general laboratory setting.Abbreviation: buprenorphine SR-LAB, sustained-release buprenorphine for veterinary useSustained-release formulations of buprenorphine for analgesic use in animals (i.e., buprenorphine SR-LAB) are produced for the veterinary market by compounding pharmacies. The extended release properties of these formulations serve as a refinement that benefits animals and their caregivers by providing multiday pain relief after a single injection.4,8,9,11,14,15 Compared with the administration of traditional analgesic medications, sustained-release analgesics provide continuous pain relief—typically for multiple days—and lessen the time, cost, stress, and hazards associated with handling an easily stressed and potentially painful animal daily (or more often).2-4,14,15 Compounding pharmacies provide crucial services in human and veterinary medicine and must comply with United States Pharmacopeia standards as enforced by state pharmacy regulators.5 For example, as a consequence of inspection by a state pharmacy board, a veterinary compounding pharmacy preparing buprenorphine SR-LAB was required to label and limit the use of buprenorphine SR-LAB to 28 d after first puncture of the vial to best ensure sterility, although the formulation was labeled with a 6-mo expiration date (shelf-life). The majority of use of buprenorphine SR-LAB at our institution is for rodents, and the 28-d use rule is problematic due to considerable amounts of remaining drug at this time point. For example, a 5 mL-vial of buprenorphine SR-LAB with a concentration of 0.5 mg/mL contains enough drug to treat 100 mice each weighing 25 g at the dose of 1 mg/kg. If the buprenorphine SR-LAB is considered to be expired after 28 d, any remaining drug is wasted, poses a potential for abuse, requires strict secure storage, and involves considerable expense for its legal destruction. These hurdles increase the likelihood that researchers will abandon attempts to use this formulation in animals, violate state-mandated standards, and engage in drug conserving and sharing schemes that are not compliant with federal law. As such, the change in shelf life complicates the use of buprenorphine SR-LAB in rodents, which in turn discourages the use of an effective analgesic that improves animal welfare. Although sterility studies for analgesic drugs such as carprofen, buprenorphine, and meloxicam have been conducted,7,10,13,16 the long-term sterility of sustained-release buprenorphine currently is unknown. Therefore, this study was conducted to test the sterility of buprenorphine SR-LAB over the stated 6-mo shelf-life. 相似文献
10.